BLA for subcutaneous formulation of Leqembi® accepted in China ...Middle East

STOCKHOLM, Jan. 6, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of Leqembi (lecanemab) for treatment of early Alzheimer's...

Hence then, the article about bla for subcutaneous formulation of leqembi accepted in china was published today ( Tuesday 06/01/2026 - 02:27 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( BLA for subcutaneous formulation of Leqembi® accepted in China )

Also on site :

• Sectra begins implementation of its first digital pathology project in Japan, aiming to improve cancer diagnostics and decrease time to treatment
• US seizes Russian oil tanker in North Atlantic
• Lanes closed on part of Route 104 westbound in Webster due to crash